IRIS - Res&Arch Institutional Research Information System - Research & Archive

The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.

Gogas BD;Bourantas CV;Garcia Garcia HM;Onuma Y;Muramatsu T;Farooq V;DILETTI, ROBERTO;van Geuns RJ;De Bruyne B;Chevalier B;Thuesen L;Smits PC;Dudek D;Koolen J;Windecker S;Whitbourn R;McClean D;Dorange C;Miquel Hebert K;Veldhof S;Rapoza R;Ormiston JA;Serruys PW

2013